BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
2024年5月24日 - 8:30PM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the
“Company”), a commercial-stage biopharmaceutical company
focused on genetic diseases and cancers, announced today that 12
oral and moderated poster presentations will be shared at the 2024
International Symposium on Amyloidosis (ISA), taking place in
Rochester, Minnesota on May 26 - 30, 2024.
BridgeBio will also host an investor call on May 29, 2024, at
5:30 pm ET to discuss the recent analyses and positive data from
the ATTRibute-CM Phase 3 trial and emerging real-world evidence in
ATTR-CM. The investor call will include presentations from Mathew
Maurer, M.D. of Columbia University Irving Medical Center and Ahmad
Masri, M.D., M.S. of Oregon Health & Science University.
To access the oral presentations and moderated poster
presentations following the Company’s participation at the 2024
ISA, please visit investor.bridgebio.com/presentations.
Oral presentation and moderated poster presentation
details:
Acoramidis impact on clinical outcomes:
- Early increase in serum transthyretin level is an
independent predictor of improved survival in ATTR cardiomyopathy:
Insights from the acoramidis phase 3 study ATTRibute-CM
- Presenter: Mathew Maurer, M.D., Columbia
University Irving Medical Center, U.S.
- Moderated poster presentation date & time:
Wednesday, May 29 at 10:00 am CT
- Acoramidis treatment-related increase in serum TTR is
associated with lower cardiovascular mortality in ATTR-CM: Insights
from ATTRibute-CM
- Presenter: Nitasha Sarswat, M.D., University
of Chicago Medicine, U.S.
- Moderated poster presentation date & time:
Wednesday, May 29 at 10:00 am CT
- Acoramidis treatment-related increase
in serum TTR is associated with a lower risk of cardiovascular
hospitalization in ATTR-CM patients: Insights from the ATTRibute-CM
trial
- Presenter: Margot Davis, M.D., Vancouver
General Hospital, CA
- Oral presentation date &
time: Wednesday, May 29 at 10:30 am CT
- Acoramidis achieves early reduction in cardiovascular
death or hospitalization in transthyretin amyloid cardiomyopathy
(ATTR-CM): Results from the ATTRibute-CM clinical trial
- Presenter: Kevin M. Alexander, M.D., Stanford
University School of Medicine, U.S.
- Oral presentation date &
time: Wednesday, May 29 at 10:30 am CT
- Higher risk of mortality in previously hospitalized
patients: Insights from ATTRibute-CM
- Presenter: John Whang, M.D., Chief Medical
Affairs Officer of BridgeBio Cardiorenal, presenting on behalf of
authors
- Moderated poster presentation date & time:
Wednesday, May 29 at 10:00 am CT
- Acoramidis improves clinical outcomes in transthyretin
amyloid cardiomyopathy [Encore]
- Presenter: Daniel Judge, M.D., Medical
University of South Carolina, U.S.
- Moderated poster presentation date & time:
Wednesday, May 29 at 10:00 am CT
- ATTRibute-CM: ITT sensitivity analysis and sub-analysis
comparing acoramidis and placebo in stage 4 CKD
[Encore]
- Presenter: Julian D. Gillmore, M.D., Ph.D.,
University College London's Centre for Amyloidosis, UK
- Moderated poster presentation date & time:
Wednesday, May 29 at 10:00 am CT
Acoramidis impact on quality of life:
- Health-related quality of life in patients with
symptomatic transthyretin amyloid cardiomyopathy treated with
acoramidis: an EQ-5D analysis from the ATTRibute-CM study
[Encore]
- Presenter: Mazen Hanna, M.D., Cleveland
Clinic, U.S.
- Moderated poster presentation date & time:
Wednesday, May 29 at 10:00 am CT
- Improved health-related quality of life in
acoramidis-treated patients with ATTR-CM, demonstrated by
improvements in KCCQ scores [Encore]
- Presenter: Brett W. Sperry, M.D., Saint Luke’s
Health System, U.S.
- Moderated poster presentation date & time:
Wednesday, May 29 at 10:00 am CT
Acoramidis impact on biomarkers of clinical relevance in
ATTR-CM:
- Acoramidis significantly improves NT-proBNP indices
that indicate ATTR-CM disease progression and predict subsequent
mortality: Insights from the ATTRibute-CM study [Encore]
- Presenter: Michel Khouri, M.D., Duke
University Medical Center, U.S.
- Moderated poster presentation date & time:
Wednesday, May 29 at 10:00 am CT
Acoramidis treatment effects reflected in structural and
functional measures by cardiac magnetic resonance
imaging:
- Acoramidis may improve cardiac function and promote
regression in ATTR-CM: Data from the ATTRibute-CM cardiac magnetic
resonance (CMR) substudy [Encore]
- Presenter: Jean-Francois Tamby, M.D., M.B.A.,
VP of Clinical Development at BridgeBio, U.S.
- Moderated poster presentation date & time:
Wednesday, May 29 at 10:00 am CT
Acoramidis and transthyretin amyloidosis
prevention:
- Rationale & design of ACT-EARLY, the acoramidis
transthyretin amyloidosis prevention trial
- Poster presenter: Pablo Garcia-Pavia, M.D.,
Ph.D., Iron Gate Majadahonda University Hospital, ES
- Moderated poster presentation date & time:
Wednesday, May 29 at 10:00 am CT
Webcast informationBridgeBio will host an
investor call and simultaneous webcast to discuss the recent
analyses and positive data from the ATTRibute-CM Phase 3 trial and
emerging real-world evidence in ATTR-CM presented at the 2024 ISA,
ESC Heart Failure 2024 and the 2024 ACC Annual Scientific Sessions
& Expo on Wednesday, May 29 at 5:30 pm ET. A link to the
webcast may be accessed from the event calendar page of BridgeBio’s
website at https://investor.bridgebio.com/. A replay of the
conference call and webcast will be archived on the Company’s
website and will be available for at least 30 days following the
event.
About BridgeBio Pharma, Inc.BridgeBio Pharma
Inc. (BridgeBio) is a commercial-stage biopharmaceutical company
founded to discover, create, test and deliver transformative
medicines to treat patients who suffer from genetic diseases and
cancers with clear genetic drivers. BridgeBio’s pipeline of
development programs ranges from early science to advanced clinical
trials. BridgeBio was founded in 2015 and its team of experienced
drug discoverers, developers, and innovators are committed to
applying advances in genetic medicine to help patients as quickly
as possible. For more information
visit bridgebio.com and follow us
on LinkedIn and Twitter.
BridgeBio Media Contact:Vikram
Balicontact@bridgebio.com (650)-789-8220
BridgeBio Pharma (NASDAQ:BBIO)
過去 株価チャート
から 5 2024 まで 6 2024
BridgeBio Pharma (NASDAQ:BBIO)
過去 株価チャート
から 6 2023 まで 6 2024